IGG and IGA antibodies to citruillinated peptides in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

被引：0
|
作者：
Riente, L
Pratesi, F
Chimenti, D
Bellitto, L
Sedie, AD
Tommasi, S
Tommasi, C
Bombardien, S
Migliorini, P
机构：
[1] Univ Pisa, Rheumatol Unit, Pisa, Italy
[2] Univ Pisa, Immunol Unit, Pisa, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：207 / 207
页数：1
相关论文
共 50 条
  • [41] Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in Ankylosing spondylitis and psoriatic arthritis
    Riente, L
    Chimenti, D
    Pratesi, F
    Delle Sedie, A
    Tommasi, S
    Tommasi, C
    Bombardieri, S
    Migliorini, P
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (05) : 920 - 924
  • [42] Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
    Ogdie, Alexis
    George, Michael D.
    Gelfand, Joel
    Dubreuil, Maureen
    Love, Thorvardur
    Baker, Joshua
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] GOLIMUMAB UTILIZATION PATTERNS AND REFILL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Ellis, L.
    Bolge, S.
    Rice, P.
    VALUE IN HEALTH, 2014, 17 (03) : A49 - A50
  • [44] Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Voulgari, Paraskevi V.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (05) : 721 - 733
  • [45] Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    Huscher, D.
    Merkesdal, S.
    Thiele, K.
    Zeidler, H.
    Schneider, M.
    Zink, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) : 1175 - 1183
  • [46] PATIENT ELIGIBILITY AND USE OF BIOLOGICS IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN THE UNITED STATES
    Narayanan, S.
    Baskett, A.
    Lu, Y.
    Hutchings, R.
    VALUE IN HEALTH, 2013, 16 (07) : A572 - A572
  • [47] Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Cantini, Fabrizio
    Niccoli, Laura
    Nannini, Carlotta
    Cassara, Emanuele
    Kaloudi, Olga
    Favalli, Ennio Giulio
    Becciolini, Andrea
    Benucci, Maurizio
    Gobbi, Francesca Li
    Guiducci, Serena
    Foti, Rosario
    Mosca, Marta
    Goletti, Delia
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) : 183 - 192
  • [48] THE EFFECT OF PREGNANCY ON ANKYLOSING-SPONDYLITIS, PSORIATIC-ARTHRITIS, AND JUVENILE RHEUMATOID-ARTHRITIS
    OSTENSEN, M
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1992, 28 (3-4) : 235 - 237
  • [49] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [50] Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
    Ruwaard, J.
    Ami, M. J. L'
    Kneepkens, E. L.
    Krieckaert, C. L. M.
    Nurmohamed, M. T.
    Hooijberg, F.
    van Kuijk, A. W. R.
    van Denderen, J. C.
    Burgemeister, L.
    Rispens, T.
    Boers, M.
    Wolbink, G. J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (02) : 129 - 136
12345